|
Originally published In Press as doi:10.1074/jbc.M110315200 on February 5, 2002
J. Biol. Chem., Vol. 277, Issue 15, 12891-12900, April 12, 2002
Mutations That Destabilize the gp41 Core Are Determinants for
Stabilizing the Simian Immunodeficiency Virus-CPmac Envelope
Glycoprotein Complex*
Jie
Liu ,
Shilong
Wang ,
James A.
Hoxie§,
Celia C.
LaBranche¶, and
Min
Lu
From the Department of Biochemistry, Weill
Medical College of Cornell University, New York, New York 10021, § Hematology-Oncology Division, the Department of Medicine,
University of Pennsylvania, Philadelphia, Pennsylvania 19104, and the
¶ Department of Surgery, Duke University Medical Center,
Durham, North Carolina 27710
Received for publication, October 26, 2001, and in revised form, January 14, 2002
 |
ABSTRACT |
The human and simian immunodeficiency viruses
(HIV and SIV) envelope glycoprotein consists of a trimer of two
noncovalently and weakly associated subunits, gp120 and gp41. Upon
binding of gp120 to cellular receptors, this labile native envelope
complex undergoes conformational changes, resulting in a stable
trimer-of-hairpins structure in gp41. Formation of the hairpin
structure is thought to mediate membrane fusion by placing the viral
and cellular membranes in close proximity. An in
vitro-derived variant of SIVmac251, denoted CPmac, has acquired
an unusually stable virion-associated gp120-gp41 complex. This unique
phenotype is conferred by five amino acid substitutions in the gp41
ectodomain. Here we characterize the structural and physicochemical
properties of the N40(L6)C38 model of the CPmac gp41 core. The 1.7-Å
resolution crystal structure of N40(L6)C38 is very similar to the
six-helix bundle structure present in the parent SIVmac251 gp41. In
both structures, three N40 peptides form a central three-stranded
coiled coil, and three C38 peptides pack in an antiparallel orientation
into hydrophobic grooves on the coiled-coil surface. Thermal unfolding
studies show that the CPmac mutations destabilize the SIVmac251
six-helix bundle by 15 kJ/mol. Our results suggest that the formation
of the gp41 trimer-of-hairpins structure is thermodynamically coupled to the conformational stability of the native envelope glycoprotein and
raise the intriguing possibility that introduction of mutations to
destabilize the six-helix bundle may lead to the stabilization of the
trimeric gp120-gp41 complex. This study suggests a potential strategy
for the production of stably folded envelope protein immunogens for HIV
vaccine development.
 |
INTRODUCTION |
For human and simian immunodeficiency viruses
(HIV1 and SIV), infection
of cells is initiated by fusion of the viral and cellular membranes.
This membrane fusion process is mediated by the viral envelope
glycoprotein and receptors on the target cell. The envelope glycoprotein is synthesized as the precursor gp160 that is processed by
proteolytic cleavage to yield two noncovalently associated subunits,
gp120 and gp41, which are organized on the viral surface as oligomeric
spikes (1, 2). gp120 determines viral tropism by binding to the cell
surface receptor CD4 and a chemokine coreceptor such as CCR-5 or CXCR-4
(Refs. 3 and 4; see also Ref. 5). The transmembrane gp41 subunit is
responsible for mediating fusion between the viral and cellular
membranes, a process that results in penetration of the viral genome
into the host cell. The native (prefusogenic) envelope conformation, as
found on the surface of the infectious virion, is inactive in fusion.
Binding of gp120/gp41 to CD4 induces initial conformational changes in
gp120 that expose the chemokine receptor binding site, and the
subsequent binding of gp120 to the chemokine receptor initiates
structural rearrangements in gp41 that promote virus- cell membrane
fusion (reviewed in Ref. 6). Recently, there has been an influx of
structural information on core fragments of gp120 in the CD4-associated
configuration and the gp41 ectodomain core (3, 6). However, it has not yet been possible to crystallize the native envelope glycoprotein complex, and thus the structural consequences of its conformational activation are not well understood.
The HIV-1 envelope glycoprotein is a primary target for vaccine
development because it is the major virus neutralization antigen during
natural viral infection. For example, the three most potent and broadly
neutralizing anti-HIV-1 antibodies yet identified, IgG1b12, 2G12, and
2F5, are known to interfere with virus-cell attachment and fusion
(7-16). However, attempts to induce neutralizing antibodies after
vaccination with individual gp120 and gp41 subunits have been
disappointing. Recent studies suggest that an immune response to the
native trimeric envelope complex rather than to viral debris
(i.e. nonnative forms of the envelope glycoprotein such as
uncleaved gp160 precursor, dissociated gp120, or gp41 ectodomain) leads
to the production of neutralizing antibodies (17-20). Since the gp120
molecule is readily dissociated or shed from virions because of its
labile, noncovalent association with the gp41 ectodomain (21-24), a
major challenge in the development of an effective HIV immunogen is to
preserve the native envelope glycoprotein structure or crucial
components thereof in vaccine preparations (reviewed in Ref. 25). Such
efforts have to date relied on approaches to stabilize the trimeric
envelope protein complex through incorporation of disulfide bonds
between the gp41 ectodomains or between the gp120 and gp41 subunits
(26-29). A safe and effective HIV-1 vaccine is not yet available,
making it important to understand the factors that influence the
native envelope conformation.
Recent work has shown that a laboratory-adapted variant of SIVmac251,
termed CPmac, exhibits increased numbers of envelope glycoprotein
spikes on virions and a remarkably stable association of the gp120 and
gp41 subunits (31). In contrast to previously described HIV isolates,
gp120 and gp41 remained associated during detergent lysis of virions
and could be co-immunoprecipitated by monoclonal antibodies to either
gp120 or gp41. Quantitative analysis of virions by high performance
liquid chromatography using chimeras between CPmac and an isogenic
derivative of SIVmac251, termed NCmac, revealed a high gp120 content on
CPmac virions (31).2 A
comparison of the CPmac and NCmac envelope glycoproteins mapped changes
responsible for this phenotype to five amino acid mutations in the gp41
ectodomain (31). These mutations are Leu-557 to Ser, Val-571 to Leu,
Lys-573 to Thr, Thr-586 to Ile, and Glu-641 to Lys substitutions (Fig.
1). Interestingly, the five mutations are either in the N-terminal
heptad-repeat region or the C-terminal heptad-repeat region (see
below). The locations of these mutations suggest that interactions
between the two -helical coiled-coil segments may contribute to the
biological phenotype of the CPmac envelope glycoprotein. To lay the
groundwork for efforts to define the structural determinants of the
stable gp120-gp41 association in CPmac, we sought to delineate the role
of the five CPmac mutations in the folding, thermodynamics, and
conformation of the gp41 ectodomain.
The transmembrane gp41 protein contains several notable features within
its ectodomain that are critical for membrane fusion activity (Fig.
1A). A hydrophobic,
glycine-rich sequence referred to as the fusion peptide is located at
the extreme NH2 terminus of gp41. This fusion peptide
region is known, in the case of influenza HA2, to insert
into the target membrane during the fusion process (32, 33). A region
following the fusion peptide has a high -helical propensity and a
4-3 heptad repeat of hydrophobic residues, a sequence feature
characteristic of coiled coils (34-36). This N-terminal heptad-repeat
region is followed by a disulfide-bonded loop and then a C-terminal
heptad repeat that precedes the transmembrane domain anchoring the
envelope glycoprotein to the viral membrane (34-36). Biochemical and
structural analyses of a protease-resistant core of gp41 indicate that
these two heptad-repeat regions form a six-helix bundle in which three
antiparallel C-terminal -helices pack into hydrophobic grooves on
the surface of an N-terminal trimeric coiled coil (37-45). This
six-helix bundle structure probably corresponds to the core of the
fusion-active trimer-of-hairpins conformation (37, 46, 47), since the
hairpin formation is structurally coupled to the apposition of viral
and cellular membranes and the actual membrane fusion event (41,
48-50). Interestingly, the trimer-of-hairpins motif is emerging as a
general feature of many viral membrane fusion proteins (cf.
Refs. 51 and 52). Peptide inhibitors that interfere with formation of
gp41 hairpin structure can inhibit HIV-1 infection (37, 53-59). Thus,
it would appear that the trimer-of-hairpins element plays a critical
role in promoting membrane fusion and controls the key process of viral entry.

View larger version (28K):
[in this window]
[in a new window]
|
Fig. 1.
Core structure of the gp41 envelope
protein. A, schematic representation of SIVmac251 gp41.
The important functional features of gp41 and the sequences of the N40
and C38 segments are shown. The recombinant N40(L6)C38 model consists
of N40 and C38 plus a six-residue linker. The disulfide bond and four
potential N-glycosylation sites are depicted. The residues
are numbered according to their position in gp160 of the SIVmac251
strain. B, helical wheel projection of the N40 and C38
sequences of SIVmac251 gp41. Five amino acid substitutions in CPmac
gp41 are shown in boldface type. The
a-g positions in each helix represent sequential positions
in the 4,3 hydrophobic heptad repeat in each sequence. The view is from
the NH2 terminus.
|
|
In this study, we have characterized the effects of the CPmac mutations
on the overall structure and stability of the gp41 ectodomain core. The
crystal structure of the CPmac gp41 core solved to 1.7-Å resolution
reveals that the mutant sequences are accommodated in the six-helix
bundle structure. The stability of the CPmac six-helix bundle decreases
by 15 kJ/mol, relative to the isogenic SIVmac 251 complex. Formation of
the gp41 hairpin structure has been proposed to provide an important
thermodynamic driving force for the conformational activation of the
envelope glycoprotein (37, 60). Our results are consistent with the hypothesis that the native envelope conformation can be stabilized by
mutations that destabilize the fusion-active gp41 core structure. By
extension, our results may also offer a simple and effective approach
to enhancing thermostability of soluble HIV envelope glycoprotein
trimers that might serve as useful immunogens in efforts to develop an
AIDS vaccine.
 |
EXPERIMENTAL PROCEDURES |
Protein Expression and Purification--
The gp41 ectodomain
segment (representing residues 555-674 of full-length gp160) from the
env gene of the SIVmac239 isolate (61) was amplified using
primers containing NdeI and BamHI restriction sites and ligated into the NdeI and BamHI sites
of the pAED4 vector (62) to make pSIVegp41. Plasmid
pN40/C38NC, encoding the SIVmac251 N40(L6)C38 protein, was
derived from pSIVegp41 by the insertion of the appropriate DNA
sequences encoding the linker residues Ser-Gly-Gly-Arg-Gly-Gly between
the COOH terminus of the N40 segment (residues 555-594) and the
NH2 terminus of the C38 segment (residues 637-674). Five
CPmac substitutions were simultaneously and individually introduced
into the N40 and C38 segments in pN40/C38NC using the method of Kunkel et al. (63) and verified by DNA sequencing. All recombinant proteins were expressed in Escherichia coli
strain BL21(DE3)/pLysS (Novagen). Cells were grown at 37 °C in LB
medium to an optical density of 0.8 at 600 nm and induced with
isopropylthio- -D-galactoside for 3-4 h. Cells were
lysed at 0 °C by glacial acetic acid. The bacterial lysate was
centrifuged (35,000 × g for 30 min) to separate the
soluble fraction from inclusion bodies. The soluble fraction, containing denatured N40(L6)C38, was dialyzed into 5% acetic acid overnight at room temperature. Proteins were purified from the soluble
fraction to homogeneity by reverse-phase high performance liquid
chromatography (Waters) on a Vydac C-18 preparative column (Hesperia,
CA), using a water-acetonitrile gradient in the presence of 0.1%
trifluoroacetic acid and lyophilized. The molecular weights of each
protein were verified by using matrix-assisted laser desorption ionization-time-of-flight mass spectrometry (PerSeptive Biosystems). The concentrations of each protein solution were determined by using
tyrosine and tryptophan absorbance at 280 nm in 6 M
guanidinium hydrochloride (GdmCl) (64).
Circular Dichroism Spectroscopy--
CD experiments were
performed on an Aviv 62A DS circular dichroism spectrometer. The
wavelength dependence of molar ellipticity, [ ], was monitored at
4 °C on a 10 µM protein solution in Tris-buffered saline (TBS) (50 mM Tris-HCl (pH 8.0), 100 mM
NaCl) from 200 to 260 nm in a 0.1-cm path length cuvette. Helix content
and the residue ellipticity, [ ], were calculated by the method of
Chen et al. (65). Thermal stability was determined by
monitoring the change in [ ]222 as a function of
temperature. Thermal melts were performed in 2 °C increments with an
equilibration time of 2 min at the desired temperature and an
integration time of 30 s, using a 1-cm path length cuvette. All
melts were reversible. Superimposable folding and unfolding curves were
observed, and >90% of the signal was regained upon cooling. The
melting temperatures, or midpoints of the cooperative thermal
unfolding transitions (Tm) were determined from
the maximum of the first derivative, with respect to the reciprocal of
the temperature, of the [ ]222 values (66). The error
in estimation of Tm is ±0.5 °C. For most of
the proteins with a melting temperature of 100 °C or higher in TBS,
thermal denaturation experiments were performed in TBS in the presence
of 2 or 3 M GdmCl.
Sedimentation Equilibrium--
Sedimentation equilibrium
measurements were performed on a Beckman XL-A (Beckman Coulter)
analytical ultracentrifuge equipped with an An-60 Ti rotor (Beckman
Coulter). Protein solutions were dialyzed overnight against TBS (pH
8.0); loaded at initial concentrations of 10, 30, and 100 µM; and analyzed at rotor speeds at 17,000 and 20,000 rpm
at 20 °C. Data sets were fitted simultaneously to a single-species
model of ln(absorbance) versus (radical
distances)2 using the program NONLIN (67). Protein partial
specific volume and solvent density were calculated as described by
Laue et al. (68). The molecular weights of N40(L6)C38
variants, except for T586I, were all within 10% of those calculated
for an ideal trimer, with no systematic deviation of the residuals.
Crystallization, Data Collection, and Structure
Determination--
Crystals were obtained using the handing drop
method of vapor diffusion by equilibrating 2-µl drops (protein
solution mixed 1:1 with reservoir solution) against a reservoir
solution at room temperature. Initial crystallization conditions were
screened by using sparse matrix crystallization kits (Crystal Screen I and II; Hampton Research, Inc.) and then optimized. Hexagonal crystals
of NCmac-N40(L6)C38 were grown from 20 mg/ml protein, 0.6 M
sodium chloride, 0.04 M barium chloride dihydrate, and 0.01 M hexadecyltrimethylammonium bromide. Rhombohedral crystals
of CPmac-N40(L6)C38 were obtained from 15 mg/ml protein and 3.8 M sodium formate. All crystals were transferred to a
cryoprotectant solution containing 15% (v/v) glycerol in the
corresponding mother liquor. Crystals were mounted in nylon loops
(Hampton Research, Riverside, CA) and flash-frozen in liquid nitrogen.
Diffraction data on NCmac-N40(L6)C38 were recorded at 100 K at the
Cornell High Energy Synchrotron Source on beamline F1 that incorporates an ADSC Quantum-4 CCD detector. Data on CPmac-N40(L6)C38 were collected
at 100 K at beamline X25 at the Brookhaven National Laboratory National
Synchrotron Light Source using a Brandeis B4 CCD detector.
Diffraction intensities were integrated by using DENZO and SCALEPACK
software (69) and reduced to structural factors with the program
TRUNCATE from the CCP4 program suite (70). The structures of the
N40(L6)C38 complexes were solved by molecular replacement with the
program AMORE (71). A monomeric model of the N40-C38 complex
derived from the crystal structure of the SIV gp41 ectodomain (45) was
used as a search model. Density interpretation and model building were
carried out with the O and CNS programs (72, 73). Iterative rounds of
manual rebuilding and refinement increased the quality of the initial
electron density maps and served to reduce model bias, as guided
chiefly by improvement in the free R factor.
Crystallographic refinements were done with the program CNS 1.0 (74).
Noncrystallographic symmetry constraints and restraints were applied
during the first few cycles of refinement of the NCmac-N40(L6)C38
structure but then were removed and not used in the final refinement.
Since molecular replacement methods can cause a final model to be
biased by the search model, the current N40(L6)C38 models were verified
by simulated annealing omit maps. The quality of coordinates was
examined by PROCHECK (75). No residues were in disallowed regions, and
99% of the amino acids were in the most favored regions of the
Ramanchandran plot. Residues 555-559, 588-594, and 668-674 of
NCmac-N40(L6)C38 and residues 555-557, 592-594, and 672-674 of
CPmac-N40(L6)C38 were left out of the model because of the absence of
interpretable electron density for these atoms. The refined coordinates
for NCmac-N40(L6)C38 (entry 1JPX) and CPmac-N40(L6)C38 (entry 1JQ0)
have been deposited in the Research Collaboratory for Structural
Bioinformatics Protein Data Bank.
 |
RESULTS |
CPmac N40(L6)C38--
Our focus is on how the five CPmac
substitutions affect the structure and stability of the NCmac gp41
ectodomain core. A protein fragment corresponding to the intact
ectodomain of gp41 tends to aggregate under physiological conditions
(37, 38) and is therefore intractable for biophysical analysis.
Accordingly, we designed a recombinant model for this soluble gp41
core. The design was based on the N36(L6)C34 polypeptide in which the
N36 and C34 helices are connected via a short peptide linker in place
of the disulfide-bonded loop region (60). The N36 peptide consists of
residues 555-590, and the C34 peptide consists of residues 637-670 of
the SIVmac251 gp41 protein sequences. For this study, we designed
analogous polypeptides that were extended by four residues at the
NH2 terminus and four residues at the COOH terminus in order to
accommodate all five CPmac mutations. The NCmac construct, designated
NCmac-N40(L6)C38, was identical to parent SIVmac251, while the CPmac
construct, designated CPmac-N40(L6)C38, contained the five CPmac
mutations noted above. For convenience, we refer to the amino acids in
N40(L6)C38 by their positions in the context of full-length gp160.
The recombinant N40(L6)C38 proteins were produced by bacterial
expression and purified by reverse-phase high performance liquid chromatography. Purified proteins were solubilized in 6 M
GdmCl and 50 mM Tris-HCl (pH 8.0), and refolded by dilution
into TBS. On the basis of CD measurements under physiological
conditions, both the NCmac- and CPmac-N40(L6)C38 proteins are well
folded and extremely stable, with greater than 95% -helical content (see Table II). Sedimentation equilibrium experiments indicate that
each protein exists in a discretely trimeric state across a
concentration range from 10 to 100 µM (Fig.
2). Taken together, these results
indicate that CPmac-N40(L6)C38, like its NCmac counterpart and
analogous polypeptides from other SIV and HIV strains (37-39), forms a
stable -helical trimer in solution. We conclude that, to a good
approximation, the introduction of the five CPmac mutations into the N-
and C-terminal heptad-repeat regions of the gp41 ectodomain does not
affect the overall protein fold of the six-helix bundle.

View larger version (20K):
[in this window]
[in a new window]
|
Fig. 2.
Biophysical characterization of the NCmac and
CPmac gp41 cores. A, thermal melts of NCmac-N40(L6)C38
(open triangles) and CPmac-N40(L6)C38
(open circles) monitored by circular dichroism at
222 nm at 10 µM protein concentration in TBS. The
filled triangles and circles show,
respectively, data for NCmac-N40(L6)C38 and CPmac-N40(L6)C38 collected
in the presence of 3 M GdmCl, a denaturant. B,
representative sedimentation equilibrium data for NCmac-N40(L6)C38
(~10 µM) were collected at 20 °C and 17,000 rpm in
TBS. Natural logarithm of absorbance at 238 nm is plotted against the
square of the radius from the axis of rotation. The data fit closely to
a trimer model. Lines expected for dimeric and tetrameric models are
indicated for comparison. The deviation in the data from the linear fit
for a trimer model is plotted (top). C,
representative data for CPmac-N40(L6)C38 (~30 µM) were
collected at 20 °C and 17,000 rpm in TBS. The deviation in the data
from the linear fit for a trimer model is plotted
(top).
|
|
Measurements of Thermal Stability--
The thermal stability of
the NCmac- and CPmac-N40(L6)C38 trimers was assessed using CD by
monitoring the ellipticity at 222 nm as a function of temperature. The
CD spectra of both of the proteins show a typical loss of -helical
content when the temperature is raised (Fig. 2A). Before the
unfolding transition, the molar ellipticity is the same for the two
proteins and increases linearly with temperature. The pre- and
post-transitional slopes and the shape of the main transition are very
similar for the NCmac and CPmac six-helix complexes, indicating that
the CPmac mutations do not detectably alter the mechanism of thermal
unfolding. At a concentration of 10 µM, the midpoint of
thermal denaturation of CPmac-N40(L6)C38 is 92 °C, as compared with
a midpoint (Tm) exceeding 100 °C for
NCmac-N40(L6)C38 at the same concentration (Fig. 2A; see
Table II). In the presence of the denaturant GdmCl at 3 M
concentration, both the NCmac- and CPmac-N40(L6)C38 proteins undergo
cooperative and reversible unfolding transitions, with Tm values of 72 and 63 °C, respectively (Fig.
2A; see Table II). The change in thermal stability between
the two molecules is ~9 °C in the presence of GdmCl. By using the
Gibbs-Helmholtz equation, together with the thermodynamic parameters
determined for the SIV N34(L6)C28 protein (76), the corresponding free
energy difference is 14.9 ± 1.5 kJ/mol for the CPmac-N40(L6)C38
trimer relative to the trimeric NCmac complex. These results support
the hypothesis that the conformational instability of the CPmac gp41
trimer-of-hairpins may enhance the stability of its native envelope
glycoprotein complex.
Crystal Structures of the NCmac- and CPmac-N40(L6)C38
Trimers--
To better understand the chemical basis of
destabilization of the six-helix bundle by the CPmac mutations, the
high resolution x-ray crystal structures of the NCmac- and
CPmac-N40(L6)C38 proteins were determined. Crystals of NCmac-N40(L6)C38
contain three monomers in the asymmetric unit, wherein each monomer is
related by a crystallographic 3-fold axis. Crystals of CPmac-N40(L6)C38
contain a monomer in the asymmetric unit, with the trimer formed around
the crystallographic 3-fold axis. Both of the structures were solved by
a molecular replacement approach. In each case, the final
2Fo Fc electron density map
and simulated annealing omit map are readily interpretable except for a
few disordered residues at the helix termini and in the six-residue
loop region. Representative examples of omit electron density maps
calculated with the final model phases are shown in Fig.
3. The NCmac-N40(L6)C38 structure was refined to an R value of 23.7%, with an
Rfree value of 28.3% over a resolution range of
50.0 to 2.3 Å. Because of asymmetric crystal contacts, the three
individual chains in the NCmac-N40(L6)C38 structure have slight
differences in conformation and degree of order, with the B chain
having a higher overall B factor (43.0 Å2) than
the A and C chains (35.3 and 40.8 Å2, respectively). The
root mean square (r.m.s.) deviations between the individual chains in
the NCmac-N40(L6)C38 noncrystallographic trimer vary from 0.62 Å (chains A and B) to 0.83 Å (chains B and C). The CPmac-N40(L6)C38
structure was refined to 1.7 Å to yield an R value of
20.9% with an Rfree value of 25.2%. Details of
data collection and refinement statistics are listed in Table
I.

View larger version (55K):
[in this window]
[in a new window]
|
Fig. 3.
Crystal structures of the NCmac and CPmac
gp41 cores. A, a portion of the -weighted
Fo Fc omit map contoured at
1.0 of NCmac-N40(L6)C38 showing core packing at the Gln-575
layer (yellow carbon, red oxygen, and
blue nitrogen bonds). The view is down the 3-fold axis of
the trimer from the NH2-terminal end. B, a
portion of the -weighted Fo Fc omit map contoured at 1.0 of CPmac-N40(L6)C38
showing core packing at the Thr-582 layer. A bound water molecule is
shown as a red sphere. Hydrogen bonds are shown
as purple dotted lines. C,
overall views of the gp41 core trimers. The left
panel shows a lateral view of superposition of the backbone
traces for NCmac-N40(L6)C38 in green and CPmac-N40(L6)C38 in
red. The NH2 termini of the N40 helices point
toward the bottom of the page and those of the C38 helices
point toward the top. The right panel
shows an axial view looking down the 3-fold axis of the trimers.
|
|
As anticipated, the overall architecture of the CPmac-N40(L6)C38 trimer
is the same as that of the wild-type NCmac complex. CPmac-N40(L6)C38
forms a rod-shaped structure of ~55 Å in length and 40 Å in
diameter (Fig. 3C). Each polypeptide chain has an -helical hairpin conformation, in which two antiparallel helices are
connected by a loop region. The N40 helices (residues 558-591) form an
interior, three-stranded -helical coiled coil. This coiled-coil core
includes ~34 residues (558-591) (the three most N-terminal and
C-terminal residues are disordered). The C38 helices (residues 637-671) pack in an antiparallel manner into hydrophobic grooves on
the surface of the trimeric coiled coil (the three most C-terminal residues are not well defined in the electron density map). The N
terminus of N40 and the C terminus of C38 are oriented at the same end
of the rod. This packing arrangement would place the fusion peptide,
located immediately before N40, and transmembrane segment, located
immediately after C38, close together. The structural differences
between the NCmac and CPmac six-helix bundles are small; the average
r.m.s. deviation in C positions of the N40 coiled coil
between the two molecules is 0.31 Å. The C38 helices can also be
superimposed, with an r.m.s. deviation of 0.48 Å. Thus, the five CPmac
mutations do not significantly alter the six-helix bundle structure.
Effects of CPmac Mutations on the Hairpin Structure--
The
N-terminal Leu-557 and Ser-557 residues are disordered in the NCmac-
and CPmac-N40(L6)C38 structures, respectively. This could mean that end
effects in the N40(L6)C38 construct cause these residues to unfold. We
focused our structural analysis on the other four well defined CPmac
substitution regions. On the surface of the N40 coiled-coil trimer, the
grooves that are the sites for C38 interaction are lined with
predominantly conserved hydrophobic residues at positions
e and g (Fig. 1B). In the NCmac N40(L6)C38 structure, Val-571, at a g position, packs
against the C38 helix through hydrophobic contacts with the Leu-654 and Ile-655 residues (Fig. 4A).
This hydrophobic effect buries 195 Å2 of
solvent-accessible surface area. In the CPmac core structure, Leu-571
interacts similarly with the C38 peptide, with a buried surface area of
213 Å2 (Fig. 4B). Thus, the Val-571 to Leu
substitution has little effect on the interface interaction and thus
the gp41 core stability. In addition, Val-571 is conserved among
different SIV strains, but it is changed to alanine in HIV-1. The
hydrophobic residue at position 571 is expected to stabilize the
six-helix bundle structure.

View larger version (61K):
[in this window]
[in a new window]
|
Fig. 4.
CPmac substitutions cause local structural
changes. A, helical packing interactions around Val-571
in NCmac-N40(L6)C38. The N40 coiled coil is represented as a molecular
surface in which the Val-571 side chain is colored green.
The C38 helix (red) is shown as a ribbon with
selected side chains that pack into the N40 interhelical groove. The
NH2 termini of the N40 helices point toward the bottom of
the page, and those of the C38 helices point toward the top.
B, helical packing interactions around Leu-571 in
CPmac-N40(L6)C38. The Leu-571 side chain is colored in
green. C, the final 2Fo Fc electron density map of NCmac-N40(L6)C38 in the
vicinity of Lys-573. Oxygen atoms are colored
red, and nitrogen atoms are blue. The map was
contoured at 1.0 . D, a surface hydrogen-bonding
interaction between Leu-569 and Thr-573 in CPmac-N40(L6)C38 as
visualized in the final 2Fo Fc
electron density contoured at 1.0 . A hydrogen bond is shown as a
purple dotted line. E, core
packing at the Thr-586 layer in NCmac-N40(L6)C38. Yellow van
der Waals surfaces identify threonines at a positions. The
view is down the 3-fold axis of the trimer from the
NH2-terminal end. Note that Lys-587 is partially ordered
and thus has not been modeled for the entire side chain. F,
core packing at the Ile-586 layer in CPmac-N40(L6)C38.
Yellow van der Waals surfaces identify isoleucines at
a positions. G, helical packing interactions
around Glu-641 in NCmac-N40(L6)C38. The Glu-641 side chain is
disordered. H, helical packing interactions around Lys-641
in CPmac-N40(L6)C38. The Lys-641 side chain is partially ordered.
|
|
The solvent-exposed b, c, and f
positions of the N40 helix are enriched with polar residues, most of
which are limited to conservative polar mutations. These polar residues
seem likely to be essential for maintaining the solubility of the gp41
core. Lys-573 is located at the b position, and its side
chain is shown clearly in the NCmac-N40(L6)C38 electron density (Fig.
4C). On the basis of distance criteria, however, the Lys-573
side chain has no potential to form electrostatic and/or polar
interactions on the surface of the six-helix bundle. In the
CPmac-N40(L6)C38 structure, the substituted Thr-573 residue forms a
hydrogen bond to the backbone carbonyl group of Leu-569 (2.76 Å) in
the preceding turn of the same helix (Fig. 4D). Our data
suggest that the stabilization energy gained from this hydrogen-bonding
interaction may compensate the unfavorable effect of low helix
propensity of threonine relative to lysine in the wild-type NCmac core.
By extension, the Lys-573 to Thr mutation per se does not
appear to alter greatly the gp41 core stability.
Whereas hydrophobic packing interactions involving residues at the
a and d positions of the N40 peptide are
important determinants of the high thermal stability of the gp41 core,
occasional buried polar residues at this coiled-coil interface impose
specificity for the trimer structure at the expense of stability (60,
77). An interplay between these hydrophobic and polar interactions is
thought to ensure that gp41 conformational changes proceed in a
concerted fashion (60, 76). In CPmac gp41, the a-position Thr-586 residue is mutated to isoleucine, a residue that is in the
corresponding position of HIV-1. In both NCmac- and CPmac-N40(L6)C38 structures, three N40 helices are packed together in the classical acute "knobs-into- holes" arrangement characteristic of trimeric coiled coils, in which the C -C bonds in
the side chains (knobs) of the a and d residues
make an acute angle with respect to the recipient holes formed by
spaces between four residues on the neighboring helices (78, 79). The
Thr-586 side chains face each other across the molecular 3-fold
symmetry axis, but their C atoms are too far from each
other to make van der Waals contacts (Fig. 4E). By contrast,
the Ile-586 residues pack against each other to form favorable
hydrophobic packing interactions (Fig. 4F). Thus, the
Thr-586 to Ile substitution contributes to the thermodynamic stability
of the N40(L6)C38 trimer.
The C-terminal end of the hydrophobic cavity on the surface of the N40
trimer features a hydrophobic cavity that has been identified as a
potentially attractive drug target (56-58). This cavity accommodates
three hydrophobic residues from the abutting C38 helix: Trp-637,
Trp-640, and Val-644. The Glu-641 residue projects outward and
does not make contacts with the coiled coil. In both NCmac- and
CPmac-N40(L6)C38 crystal structures, the Glu-641 and Lys-641 side
chains have not been modeled for lack of connected electron density,
presumably indicating disorder (Fig. 4, G and H).
Interestingly, Glu-641 and its conservative aspartic acid substitution
are completely conserved in 260 of 263 fully sequenced HIV-1, HIV-2,
and SIV isolates (HIV-1 sequence data base, July 2001, Los Alamos
National Laboratory). The remaining three isolates possess a lysine
substitution at this position. The Glu/Asp-641 residue may be critical
for membrane fusion due to the requirement of electrostatic
complementarity in a different conformational state of gp41.
NCmac-N40(L6)C38 Variants with Single CPmac Mutations--
Our
crystallographic analysis suggests that the Lys-573 to Thr and Thr-586
to Ile mutations probably stabilize the NCmac gp41 core, while its
stability is essentially unaffected by the Val-571 to Leu and Glu-641
to Lys mutations. Given that the CPmac hairpin structure is less stable
than the corresponding NCmac structure, it would appear that the
Leu-557 to Ser mutation markedly destabilizes the six-helix bundle. To
directly test this hypothesis, we introduced each of the five CPmac
mutations into NCmac-N40(L6)C38. The resulting single-point mutants
were named by the position of the substitution. Sedimentation
equilibrium measurements indicate that the L577S, V571L, K573T, and
E641K variants sediment as clean trimers (Table II). T586I is also trimeric in solution
and exhibits no systematic dependence of molecular weight on
concentrations between 10 and 100 µM (Table II). However,
a systematic trend is observed in the residuals between the data and
the linear fit (Fig. 5A),
suggesting that T586I is prone to aggregation. On the basis of CD
measurements at 10 µM protein concentration in TBS,
V571L, K573T, T586I, E641K, and NCmac-N40(L6)C38 (wild type) have a
thermal stability that exceeds 100 °C, whereas the L557S mutant
exhibits a cooperative melt with a Tm of
73 °C (Table II). In the presence of 2 M GdmCl, L557S
has a melting temperature 30 °C lower and is ~49.5 kJ/mol less
stable than the wild type (Table II). The V571L and E641K mutants have
the same stability as the wild type (Fig. 5B; Table II). The
Lys-573 to Thr mutation has a small favorable residual stabilization of
~6.6 kJ/mol (Fig. 5B; Table II). This may be due to a
hydrogen-bonding interaction between the Leu-569 and Thr-573 residues
seen in the CPmac-N40(L6)C38 crystal structure. The T586I mutant shows
stabilization of ~38.0 kJ/mol, with an apparent elevation of the
melting temperature relative to the wild type of about 23 °C in the
presence of 3 M GdmCl (Fig. 5B; Table II). This
greater stabilization effect can be ascribed to the van der Waals and
hydrophobic interactions associated with the Ile-586 residues. By
taking the sum of interactions in the five single mutants combined, the
overall residual destabilization amounts to 4.9 kJ/mol (L557S (49.5 kJ/mol) (K573T + T586I) (44.6 kJ/mol)). This value is below
that in CPmac-N40(L6)C38 (14.9 kJ/mol), suggesting that coupling
interactions including structural relaxation in a coiled coil
complicate parsing the free energy in this manner.

View larger version (18K):
[in this window]
[in a new window]
|
Fig. 5.
Properties of mutant N40(L6)C38
proteins. A, equilibrium sedimentation data (17,000 rpm) of T586I collected at 20 °C in TBS at ~10 µM
protein concentration. Natural logarithm of absorbance at 239 nm is
plotted against the square of the radius from the axis of rotation. A
dashed line indicates the calculated values for a
trimeric complex. Data fit closely to a trimer model but with
systematic residuals. B, thermal unfolding monitored by
circular dichroism at 222 nm for V571L (open
circles), K573T (filled circles),
T586I (filled triangles), and E641K
(open triangles) at 10 µM protein
concentration in TBS in the presence of 3 M GdmCl. The
decrease in the fraction of a folded molecule is shown as a function of
temperature.
|
|
 |
DISCUSSION |
The production and characterization of the native trimeric
gp120-gp41 complex have been hindered by the lability of intersubunit interactions. Initial attempts at making stable envelope glycoprotein trimers involved the disruption of the proteolytic cleavage site between gp120 and gp41 (80-83). Such proteins are also truncated N-terminal to the membrane-spinning region of gp41, so they are efficiently secreted as soluble proteins. Although the uncleaved gp140
proteins form stable oligomers (Ref. 84 and references therein), their
conformations are different from those of the mature envelope
glycoproteins, as inferred from changes in antibody binding (18, 85,
86). Immunogenicity studies carried out to date with these gp140
proteins have not been particularly encouraging, as broadly
neutralizing antibodies to HIV-1 have not been elicited (28, 29, 83,
87-89). Recent attempts have been made to stabilize soluble gp140
proteins with the natural gp120-gp41 cleavage site preserved, but with
a disulfide bond introduced between gp120 and gp41 (27).
Notwithstanding the labile nature of the cleaved gp140 oligomers, they
have antigenic properties that resemble those of the virion-associated
envelope complex (27). Clearly, one of the major obstacles in the
design of vaccines inducing humoral immunity is to develop envelope
protein preparations that have a correctly folded native conformation
and oligomerization state.
Interestingly, CPmac, unlike many other laboratory-adapted HIV-1 and
SIV strains, displays an unusually stable gp120-gp41 interaction in the
envelope glycoprotein spike (31). This tight intersubunit association
is correlated with an increase in gp120 retention and high envelope
spike count on virions (30, 31). In addition, gp120 and gp41 isolated
from CPmac virions are still associated in the presence of detergent.
Importantly, the CPmac envelope glycoprotein is fully cleaved and
fusion-competent (31). It is surprising that this phenotype results
from five point mutations within the ectodomain of gp41
(31).2 Hence, the CPmac envelope glycoprotein provides an
excellent system for conformational and functional studies of the
native gp120-gp41 complex as well as for understanding the physical
basis of the gp120-gp41 interaction. We have investigated the role of the CPmac mutations in conferring structural specificity and
conformational stability to the gp41 core. Our results show that
CPmac-N40(L6)C38, like the wild-type molecule, forms a trimer of
helical hairpins in solution. The x-ray crystallographic analysis
indicates that the CPmac mutation sequences are well accommodated in
the six-helix bundle structure by forming helical packing interactions
with different sets of atoms. The NCmac and CPmac six-helix bundles structures can be superimposed, with an r.m.s. difference of 0.51 Å.
The major differences appear in the central N-terminal coiled-coil region, where four amino acid substitutions occur in CPmac gp41. Thermal unfolding studies show that the CPmac mutations destabilize the
six-helix bundle by 15 kJ/mol, an apparent decrease of the melting
temperature relative to wild-type of about 9 °C. Furthermore, the
buried Ser-557 residue, located at the interhelical interface g position of the N40 coiled coil, appears to be the key
determinant for the reduced stability of the CPmac gp41 core. It is
possible that the destabilizing effects observed here may be related to the biological properties of the CPmac envelope complex (see below).
Current models for virus-mediated membrane fusion suggest that viral
fusion proteins undergo conformational changes to become fusion-active
(reviewed in Ref. 6). The most notable example is the
"spring-loaded" mechanism for activation of the hemagglutinin (HA)
protein of influenza virus (90-92). The native
HA1-HA2 complex on virions exists in a
metastable conformation, distinct from the fusion-active state (90).
The low pH environment of endosomes induces a major refolding of
HA2, in which a nonhelical loop converts to a
three-stranded coiled coil, projecting the fusion peptide region on the
top of the molecule, where it can reach the target membrane (91, 92).
It has became apparent that the fusion potential of HA is activated by
destabilization of the metastable native conformation (93, 94).
For HIV-1 and SIV, membrane fusion is also thought to be promoted by a
series of conformational changes in the envelope glycoprotein, although
few details are understood (reviewed by Refs. 47, 51, and 95).
Considerable evidence now suggests that gp41 exists in at least three
different conformations: (i) a metastable native state, which is
stabilized by extensive interactions with the gp120 surface subunit,
(ii) a "prehairpin" intermediate, formed by exposure of the fusion
peptide region and concurrent formation of the N-terminal coiled coil
(49, 96-98), and (iii) the fusogenic hairpin form, where the
C-terminal helix associates with the N-terminal coiled coil to induce
apposition of membranes for fusion (41, 48, 49). It is thought that
free energy made available from hairpin formation can be harnessed to
overcome the activation energy barrier for the fusion of two bilayers
(e.g. Refs. 47 and 60), although it is unclear how the
thermodynamics of the gp41 structural rearrangements are coupled
directly to membrane fusion events. Several lines of evidence suggest
that the conformational stability of the trimer-of-hairpins structure
determines the membrane-fusion properties of the gp120-gp41 complex.
First, the folding and stability of the gp41 core bearing mutations in
one of the a positions of the N-terminal heptad-repeat
correlate with severity of the in vivo phenotypes observed
in cells expressing the mutant HIV-1 envelope proteins (98, 99). These
results are consistent with the notion that formation of the N-terminal
three-stranded coiled coil occurs as an early event in the gp41
refolding process. Second, replacement of a conserved glutamine
(Gln-652) at the buried face of the C-terminal helix by leucine
increases HIV-1 infectivity (100). This fusion-enhancing mutation
strengthens packing interactions between the N- and the C-terminal
helices, stabilizing the six-helix bundle structure (101). Third,
interhelical packing interactions appear to underlie the antiviral
activity of peptides derived from the C-terminal helical region (called
C-peptides) (43, 101, 102). Studies from several groups support a
mechanism of dominant negative inhibition in which exogenous C-peptides
bind to the N-terminal region of the prehairpin structure and prevent formation of the fusogenic gp41 trimer of hairpins (37, 49, 97, 103,
104).
The detrimental effects of the CPmac mutations on the gp41 core
structure identified here, together with other available evidence, can
be interpreted to support a minimal hypothesis: namely, mutations that
destabilize the fusogenic hairpin structure might block gp41 activation
and shift the conformational equilibrium of the envelope glycoprotein
toward the native state, possibly leading to stabilization of the
native envelope complex (60, 77). Therefore, the CPmac mutations could
tip the balance between the metastable native and stable fusogenic
envelope conformations by destabilizing the six-helix bundle.
Alternatively, these mutations could directly stabilize the native
envelope complex. It is widely believed that in the native state, the
N-terminal heptad-repeat region of gp41 exists in a non-coiled-coil
conformation, such that gp120 shedding or displacement may allow
formation of the N40 coiled coil (54, 98, 99, 105, 106). Thus, gp120
may serve as a clamp that binds to this N-terminal region, repressing
formation of the six-helix bundle structure. The CPmac substitutions
could enhance gp120-gp41 interaction, thereby stabilizing the native
envelope structure. Nonetheless, our data show that an apparent
increase in the stability of the CPmac envelope glycoprotein
complex is accompanied by a decrease in the stability of the
fusogenic gp41 hairpin structure. If this proves to be generally true,
this finding may lead to a novel approach to stabilize the HIV-1
envelope glycoprotein complex for structural and immunogenicity studies.
 |
ACKNOWLEDGEMENTS |
We thank Wentao Jin and Xiuwen Ma for
excellent technical assistance and Neville Kallenbach for critical
reading of the manuscript.
 |
FOOTNOTES |
*
This work was supported by National Institutes of Health
Grants AI49784, AI50504, and AI42382.The costs of publication of this
article were defrayed in part by the
payment of page charges. The article
must therefore be hereby marked
"advertisement" in accordance with 18 U.S.C. Section
1734 solely to indicate this fact.
The atomic coordinates and the structure factors (code 1JPX and 1JQ0) have been deposited in the Protein Data Bank, Research Collaboratory for Structural Bioinformatics, Rutgers University, New Brunswick, NJ (http://www.rcsb.org/).
To whom correspondence should be addressed: Dept. of
Biochemistry, Weill Medical College of Cornell University, 1300 York Ave., New York, NY 10021. Tel.: 212-746-6562; Fax: 212-746-8875; E-mail: mlu@mail.med.cornell.edu.
Published, JBC Papers in Press, February 5, 2002, DOI 10.1074/jbc.M110315200
2
J. A. Hoxie and E. Chertova, unpublished data.
 |
ABBREVIATIONS |
The abbreviations used are:
HIV, human
immunodeficiency virus;
SIV, simian immunodeficiency virus;
GdmCl, guanidinium hydrochloride;
TBS, Tris-buffered saline;
r.m.s., root mean
square;
HA, hemagglutinin.
 |
REFERENCES |
| 1.
|
Hunter, E.,
and Swanstrom, R.
(1990)
Curr. Topics Microbiol. Immunol.
157,
187-253[Medline]
[Order article via Infotrieve]
|
| 2.
|
Luciw, P. A.
(1996)
in
Fields Virology
(Fields, B. N.
, Knipe, D. M.
, Howley, P. M.
, Chanock, R. M.
, Melinick, J. L.
, Monath, T. P.
, Roizman, B.
, and Straus, S. E., eds)
, p. 1881, Lippincott-Raven Publishers, Philadelphia
|
| 3.
|
Kwong, P. D.,
Wyatt, R.,
Robinson, J.,
Sweet, R. W.,
Sodroski, J.,
and Hendrickson, W. A.
(1998)
Nature
393,
648-659[CrossRef][Medline]
[Order article via Infotrieve]
|
| 4.
|
Rizzuto, C. D.,
Wyatt, R.,
Hernandez-Ramos, N.,
Sun, Y.,
Kwong, P. D.,
Hendrickson, W. A.,
and Sodroski, J.
(1998)
Science
280,
1949-1953[Abstract/Free Full Text]
|
| 5.
|
Berger, E. A.,
Murphy, P. M.,
and Farber, J. M.
(1999)
Annu. Rev. Immunol.
17,
657-700[CrossRef][Medline]
[Order article via Infotrieve]
|
| 6.
|
Eckert, D. M.,
and Kim, P. S.
(2001)
Annu. Rev. Biochem.
70,
777-810[CrossRef][Medline]
[Order article via Infotrieve]
|
| 7.
|
Burton, D. R.,
Pyati, J.,
Koduri, R.,
Thornton, G. B.,
Sawyer, L. S. W.,
Hendry, R. M.,
Dunlop, N.,
Nara, P. L.,
Lamacchia, M.,
Garratty, E.,
Stiehm, E. R.,
Bryson, Y. J.,
Moore, J. P., Ho, D. D.,
and Barbas, C. F., III
(1994)
Science
266,
1024-1027[Abstract/Free Full Text]
|
| 8.
|
Muster, T.,
Guinea, R.,
Trkola, A.,
Purtscher, M.,
Klima, A.,
Steindl, F.,
Palese, P.,
and Katinger, H.
(1994)
J. Virol.
68,
4031-4034[Abstract/Free Full Text]
|
| 9.
|
Roben, P.,
Moore, J. P.,
Thali, M.,
Sodroski, J.,
Barnas, C. F., III,
and Burton, D. R.
(1994)
J. Virol.
68,
4821-4828[Abstract/Free Full Text]
|
| 10.
|
Sattentau, Q. J.,
Zolla-Pazner, S.,
and Poignard, P.
(1995)
Virology
206,
713-717[CrossRef][Medline]
[Order article via Infotrieve]
|
| 11.
|
Sullivan, N.,
Sun, Y., Li, J.,
Hofmann, W.,
and Sodroski, J.
(1995)
J. Virol.
69,
4413-4422[Abstract]
|
| 12.
|
Sattentau, Q. J.,
and Moore, J. P.
(1995)
J. Exp. Med.
182,
185-196[Abstract/Free Full Text]
|
| 13.
|
Trkola, A.,
Purtscher, M.,
Muster, T.,
Ballaun, C.,
Buchacher, A.,
Sullivan, N.,
Srinivasan, K.,
Sodroski, J.,
Moore, J. P.,
and Katinger, H.
(1996)
J. Virol.
70,
1100-1108[Abstract]
|
| 14.
|
Fouts, T. R.,
Binley, J. M.,
Trkola, A.,
Robinson, J. E.,
and Moore, J. P.
(1997)
J. Virol.
71,
2779-2785[Abstract]
|
| 15.
|
Parker, C. E.,
Deterding, L. J.,
Hager-Braun, C.,
Binley, J. M.,
Schuelke, N.,
Katinger, H.,
Moore, J. P.,
and Tomer, K. B.
(2001)
J. Virol.
75,
10906-10911[Abstract/Free Full Text]
|
| 16.
|
Zwick, M. B.,
Labrijn, A. F.,
Wang, M.,
Spenlehauer, C.,
Saphire, E. O.,
Binley, J. M.,
Moore, J. P.,
Stiegler, G.,
Katinger, H.,
Burton, D. R.,
and Parren, P. W. H. I.
(2001)
J. Virol.
75,
10892-10905[Abstract/Free Full Text]
|
| 17.
|
Moore, J. P.,
and Ho, D. D.
(1995)
J. Acquired Immune Defic. Syndr.
9,
S117-S136
|
| 18.
|
Burton, D. R.,
and Montefiori, D. C.
(1997)
J. Acquired Immune Defic. Syndr.
11,
587-598
|
| 19.
|
Parren, P. W. H. I.,
Burton, D. R.,
and Sattentau, Q. J.
(1997)
Nat. Med.
3,
366-367[Medline]
[Order article via Infotrieve]
|
| 20.
|
Parren, P. W. H. I.,
Moore, J. P.,
Burton, D. R.,
and Sattentau, Q. J.
(1999)
J. Acquired Immune Defic. Syndr.
13,
S137-S162
|
| 21.
|
Gelderblom, H. R.,
Reupke, H.,
and Pauli, G.
(1985)
Lancet
ii,
1016-1017
|
| 22.
|
Moore, J. P.,
McKeating, J. A.,
Weiss, R. A.,
and Sattentau, Q. J.
(1990)
Science
250,
1139-1142[Abstract/Free Full Text]
|
| 23.
|
McKeating, J. A.,
McKnight, A.,
and Moore, J. P.
(1991)
J. Virol.
65,
852-860[Abstract/Free Full Text]
|
| 24.
|
Poignard, P.,
Fotus, T.,
Naniche, D.,
Moore, J. P.,
and Sattentau, Q. J.
(1996)
J. Exp. Med.
183,
473-484[Abstract/Free Full Text]
|
| 25.
|
Wyatt, R.,
and Sodroski, J.
(1998)
Science
280,
1884-1888[Abstract/Free Full Text]
|
| 26.
|
Farzan, M.,
Choe, H.,
Desjardins, E.,
Sun, Y.,
Kuhn, J.,
Cao, J.,
Archambault, D.,
Kolchinsky, P.,
Koch, M.,
Wyatt, R.,
and Sodroski, J.
(1998)
J. Virol.
72,
7620-7625[Abstract/Free Full Text]
|
| 27.
|
Binley, J. M.,
Sanders, R. W.,
Clas, B.,
Schuelke, N.,
Master, A.,
Guo, Y.,
Kajumo, F.,
Anselma, D. J.,
Maddon, P. J.,
Olson, W. C.,
and Moore, J. P.
(2000)
J. Virol.
74,
627-643[Abstract/Free Full Text]
|
| 28.
|
Yang, X.,
Farzan, M.,
Wyatt, R.,
and Sodroski, J.
(2000)
J. Virol.
74,
5716-5725[Abstract/Free Full Text]
|
| 29.
|
Yang, X.,
Florin, L.,
Farzan, M.,
Kolchinsky, P.,
Kwong, P. D.,
Sodroski, J.,
and Wyatt, R.
(2000)
J. Virol.
74,
4746-4754[Abstract/Free Full Text]
|
| 30.
|
LaBranche, C. C.,
Sauter, M. S.,
Haggarty, B. S.,
Vance, P. J.,
Romano, J.,
Hart, T. K.,
Bugelski, P. J.,
and Hoxie, J. A.
(1994)
J. Virol.
68,
5509-5522[Abstract/Free Full Text]
|
| 31.
|
LaBranche, C. C.,
Sauter, M. S.,
Haggarty, B. S.,
Vance, P. J.,
Romano, J.,
Hart, T. K.,
Bugelski, P. J.,
Marsh, M.,
and Hoxie, J. A.
(1995)
J. Virol.
69,
5217-5227[Abstract]
|
| 32.
|
Stegmann, T.,
Delfino, J. M.,
Richards, F. M.,
and Helenius, A.
(1991)
J. Biol. Chem.
266,
18404-18410[Abstract/Free Full Text]
|
| 33.
|
Tsurudome, M.,
Gluck, R.,
Graf, R.,
Falchetto, R.,
Schaller, U.,
and Brunner, J.
(1992)
J. Biol. Chem.
267,
20225-20232[Abstract/Free Full Text]
|
| 34.
|
Delwart, E. J.,
Mosialos, G.,
and Gilmore, T.
(1990)
AIDS Res. Hum. Retroviruses
6,
703-706[Medline]
[Order article via Infotrieve]
|
| 35.
|
Chambers, P.,
Pringle, C. R.,
and Easton, A. J.
(1990)
J. Gen. Virol.
71,
3075-3080[Abstract/Free Full Text]
|
| 36.
|
Gallaher, W. R.,
Ball, J. M.,
Garry, R. F.,
Griffin, M. C.,
and Montelaro, R. C.
(1989)
AIDS Res. Hum. Retroviruses
5,
431-440[Medline]
[Order article via Infotrieve]
|
| 37.
|
Lu, M.,
Blacklow, S. C.,
and Kim, P. S.
(1995)
Nat. Struct. Biol.
2,
1075-1082[CrossRef][Medline]
[Order article via Infotrieve]
|
| 38.
|
Blacklow, S. C., Lu, M.,
and Kim, P. S.
(1995)
Biochemistry
34,
14955-14962[CrossRef][Medline]
[Order article via Infotrieve]
|
| 39.
|
Lu, M.,
and Kim, P. S.
(1997)
J. Biomol. Struct. Dyn.
15,
465-471[Medline]
[Order article via Infotrieve]
|
| 40.
|
Chan, D. C.,
Fass, D.,
Berger, J. M.,
and Kim, P. S.
(1997)
Cell
89,
263-273[CrossRef][Medline]
[Order article via Infotrieve]
|
| 41.
|
Weissenhorn, W.,
Dessen, A.,
Harrison, S. C.,
Skehel, J. J.,
and Wiley, D. C.
(1997)
Nature
387,
426-430[CrossRef][Medline]
[Order article via Infotrieve]
|
| 42.
|
Tan, K.,
Liu, J.,
Wang, J.,
Shen, S.,
and Lu, M.
(1997)
Proc. Natl. Acad. Sci. U. S. A.
94,
12303-12308[Abstract/Free Full Text]
|
| 43.
|
Malashkevich, V. N.,
Chan, D. C.,
Chutkowski, C. T.,
and Kim, P. S.
(1998)
Proc. Natl. Acad. Sci. U. S. A.
95,
9134-9139[Abstract/Free Full Text]
|
| 44.
|
Caffrey, M.,
Cai, M.,
Kaufman, J.,
Stahl, S. J.,
Wingfield, P. T.,
Covell, D. G.,
Gronenborn, A. M.,
and Clore, G. M.
(1998)
EMBO J.
17,
4572-4584[CrossRef][Medline]
[Order article via Infotrieve]
|
| 45.
|
Yang, Z.-N.,
Mueser, T. C.,
Kaufman, J.,
Stahl, S. J.,
Wingfield, P. T.,
and Hyde, C. C.
(1999)
J. Struct. Biol.
126,
131-144[CrossRef][Medline]
[Order article via Infotrieve]
|
| 46.
|
Jiang, S.,
Lin, K.,
and Lu, M.
(1998)
J. Virol.
72,
10213-10217[Abstract/Free Full Text]
|
| 47.
|
Chan, D. C.,
and Kim, P. S.
(1998)
Cell
93,
681-684[CrossRef][Medline]
[Order article via Infotrieve]
|
| 48.
|
Hughson, F. M.
(1997)
Curr. Biol.
7,
R565-R569[CrossRef][Medline]
[Order article via Infotrieve]
|
| 49.
|
Furuta, R. A.,
Wild, C. T.,
Weng, Y.,
and Weiss, C. D.
(1998)
Nat. Struct. Biol.
5,
276-279[CrossRef][Medline]
[Order article via Infotrieve]
|
| 50.
|
Melikyan, G. B.,
Markosyan, R. M.,
Hemmati, H.,
Delmedico, M. K.,
Lambert, D. M.,
and Cohen, F. S.
(2000)
J. Cell Biol.
151,
413-424[Abstract/Free Full Text]
|
| 51.
|
Skehel, J. J.,
and Wiley, D. C.
(1998)
Cell
95,
871-874[CrossRef][Medline]
[Order article via Infotrieve]
|
| 52.
|
Baker, K. A.,
Dutch, R. E.,
Lamb, R. A.,
and Jardetzky, T. S.
(1999)
Mol. Cell
3,
309-319[CrossRef][Medline]
[Order article via Infotrieve]
|
| 53.
|
Jiang, S.,
Lin, K.,
Strick, N.,
and Neurath, A. R.
(1993)
Nature
365,
113[Medline]
[Order article via Infotrieve]
|
| 54.
|
Wild, C. T.,
Shugars, D. C.,
Greenwell, T. K.,
McDanal, C. B.,
and Matthews, T. J.
(1994)
Proc. Natl. Acad. Sci. U. S. A.
91,
9770-9774[Abstract/Free Full Text]
|
| 55.
|
Kilby, J. M.,
Hopkins, S.,
Venetta, T. M.,
DiMassimo, B.,
Cloud, G. A.,
Lee, J. Y.,
Alldredge, Y.,
Hunter, E.,
Lambert, D.,
Bolognesi, D.,
Matthews, T.,
Johnson, M. R.,
Nowak, M. A.,
Shaw, G. M.,
and Saag, M. S.
(1998)
Nat. Med.
4,
1302-1307[CrossRef][Medline]
[Order article via Infotrieve]
|
| 56.
|
Eckert, D. M.,
Malashkevich, V. N.,
Hong, L. H.,
Carr, P. A.,
and Kim, P. S.
(1999)
Cell
99,
103-115[CrossRef][Medline]
[Order article via Infotrieve]
|
| 57.
|
Ferrer, M.,
Kapoor, T. M.,
Strassmaier, T.,
Weissenhorn, W.,
Skehel, J. J.,
Oprian, D.,
Schreiber, S.,
Wiley, D. C.,
and Harrison, S. C.
(1999)
Nat. Struct. Biol.
6,
953-960[CrossRef][Medline]
[Order article via Infotrieve]
|
| 58.
|
Sodroski, J.
(1999)
Cell
99,
243-246[CrossRef][Medline]
[Order article via Infotrieve]
|
| 59.
|
Root, M. J.,
Kay, M. S.,
and Kim, P. S.
(2001)
Science
291,
884-888[CrossRef][Medline]
[Order article via Infotrieve]
|
| 60.
|
Ji, H.,
Bracken, C.,
and Lu, M.
(2000)
Biochemistry
39,
676-685[CrossRef][Medline]
[Order article via Infotrieve]
|
| 61.
|
Gibbs, J. S.,
Regier, D. A.,
and Desrosiers, R. C.
(1994)
AIDS Res. Hum. Retroviruses
10,
607-616[Medline]
[Order article via Infotrieve]
|
| 62.
|
Doering, D. S.,
and Matsudaira, P.
(1996)
Biochemistry
35,
12677-12685[CrossRef][Medline]
[Order article via Infotrieve]
|
| 63.
|
Kunkel, T. A.,
Roberts, J. D.,
and Zakour, R. A.
(1987)
Methods Enzymol.
154,
367-382[Medline]
[Order article via Infotrieve]
|
| 64.
|
Edelhoch, H.
(1967)
Biochemistry
6,
1948-1954[CrossRef][Medline]
[Order article via Infotrieve]
|
| 65.
|
Chen, Y. -H.,
Yang, J. T.,
and Chau, K. H.
(1974)
Biochemistry
13,
3350-3359[CrossRef][Medline]
[Order article via Infotrieve]
|
| 66.
|
Cantor, C.,
and Schimmel, P.
(1980)
Biophysical Chemistry, Part III
, p. 1131, W. H. Freeman and Co., New York
|
| 67.
|
Johnson, M. L.,
Correia, J. J.,
Yphantis, D. A.,
and Halvorson, H. R.
(1981)
Biophys. J.
36,
575-588[Medline]
[Order article via Infotrieve]
|
| 68.
|
Laue, T. M.,
Shah, B. D.,
Ridgeway, T. M.,
and Pelletier, S. L.
(1992)
in
Analytical Ultracentrifugation in Biochemistry and Polymer Science
(Harding, S. E.
, Rowe, A. J.
, and Horton, J. C., eds)
, p. 90, Royal Society of Chemistry, Cambridge
|
| 69.
|
Otwinowski, Z.,
and Minor, W.
(1997)
Methods Enzymol.
276,
307-326
|
| 70.
|
Collaborative Computational Project 4.
(1994)
Acta Crystallogr. Sect. D
50,
760-763[CrossRef][Medline]
[Order article via Infotrieve]
|
| 71.
|
Navaza, J.
(1994)
Acta Crystallogr. Sect. A
50,
157-163[CrossRef]
|
| 72.
|
Jones, T. A.,
Zou, J. W.,
Cowan, S. W.,
and Kjelgaard, M.
(1991)
Acta Crystallogr. Sect. D
47,
110-119
|
| 73.
|
Brüunger, A. T.
(1992)
XPLOR version 3.1: A System for X-ray Crystallography and NMR
, Yale University Press, New Haven, CT
|
| 74.
|
Brünger, A. T.,
Adams, P. D.,
Clore, G. M.,
DeLano, W. L.,
Gros, P.,
Grosse-Kunstleve, R. W.,
Jiang, J.-S.,
Kuszewski, J.,
Nilges, M.,
Pannu, N. S.,
Read, R. J.,
Rice, L. M.,
Simonson, T.,
and Warren, G. L.
(1998)
Acta Crystallogr. Sect. D
54,
905-921[CrossRef][Medline]
[Order article via Infotrieve]
|
| 75.
|
Laskowski, R. A.,
MacArthur, M. V.,
Moss, D. D.,
and Thornton, J. M.
(1993)
J. Appl. Crystallogr.
26,
283-291[CrossRef]
|
| 76.
|
Jelesarov, I.,
and Lu, M.
(2001)
J. Mol. Biol.
307,
637-656[CrossRef][Medline]
[Order article via Infotrieve]
|
| 77.
|
Liu, J.,
Shu, W.,
Fagan, M. B.,
Nunberg, J. H.,
and Lu, M.
(2001)
Biochemistry
40,
2797-2807[CrossRef][Medline]
[Order article via Infotrieve]
|
| 78.
|
Crick, F. H. C.
(1953)
Acta Crystallogr.
6,
689-697[CrossRef]
|
| 79.
|
Harbury, P. B.,
Kim, P. S.,
and Alber, T.
(1994)
Nature
371,
80-83[CrossRef][Medline]
[Order article via Infotrieve]
|
| 80.
|
Berman, P. W.,
Nunes, W. M.,
and Haffar, O. K.
(1988)
J. Virol.
62,
3135-3142[Abstract/Free Full Text]
|
| 81.
|
Earl, P. L.,
Doms, R. W.,
and Moss, B.
(1990)
Proc. Natl. Acad. Sci. U. S. A.
87,
648-652[Abstract/Free Full Text]
|
| 82.
|
Earl, P. L.,
Broder, C. C.,
Long, D.,
Lee, S. A.,
Peterson, J.,
Chakrabarti, S.,
Doms, R. W.,
and Moss, B.
(1994)
J. Virol.
68,
3015-3026[Abstract/Free Full Text]
|
| 83.
|
Earl, P. L.,
Broder, C. C.,
Doms, R. W.,
and Moss, B.
(1997)
J. Viol.
71,
2674-2684[Abstract]
|
| 84.
|
Edinger, A. L.,
Blanpain, C.,
Kuntsman, K. J.,
Wolinsky, S. M.,
Parmentier, M.,
and Doms, R. W.
(1999)
J. Virol.
73,
4062-4073[Abstract/Free Full Text]
|
| 85.
|
Sugiura, W.
(1999)
Virology
254,
257-267[CrossRef][Medline]
[Order article via Infotrieve]
|
| 86.
|
Stamatatos, L.,
Lim, M.,
and Cheng-Mayer, C.
(2000)
AIDS Res. Hum. Retroviruses
16,
981-994[CrossRef][Medline]
[Order article via Infotrieve]
|
| 87.
|
Richardson, Jr., T. M.,
Stryjewski, B. L.,
Broder, C. C.,
Hoxie, J. A.,
Mascola, J. R.,
Earl, P. L.,
and Doms, R. W.
(1996)
J. Virol.
70,
753-762[Abstract]
|
| 88.
|
VanCott, T. C.,
Mascola, J. R.,
Kaminski, R. W.,
Kalyanraman, V.,
Hallberg, P. L.,
Burnett, P. R.,
Ulrich, J. T.,
Rechtman, D. J.,
and Birx, D. L.
(1997)
J. Virol.
71,
4319-4330[Abstract]
|
| 89.
|
Yang, X.,
Wyatt, R.,
and Sodroski, J.
(2001)
J. Virol.
75,
1165-1171[Abstract/Free Full Text]
|
| 90.
|
Wilson, I. A.,
Skehel, J. J.,
and Wiley, D. C.
(1981)
Nature
289,
366-375[CrossRef][Medline]
[Order article via Infotrieve]
|
| 91.
|
Carr, C. M.,
and Kim, P. S.
(1993)
Cell
73,
823-832[CrossRef][Medline]
[Order article via Infotrieve]
|
| 92.
|
Bullough, P. A.,
Hughson, F. M.,
Skehel, J. J.,
and Wiley, D. C.
(1994)
Nature
371,
37-43[CrossRef][Medline]
[Order article via Infotrieve]
|
| 93.
|
Chen, J.,
Wharton, S. A.,
Weissenhorn, W.,
Calder, L. J.,
Hughson, F. M.,
Skehel, J. J.,
and Wiley, D. C.
(1995)
Proc. Natl. Acad. Sci. U. S. A.
92,
12205-12209[Abstract/Free Full Text]
|
| 94.
|
Carr, C. M.,
Chaudhry, C.,
and Kim, P. S.
(1997)
Proc. Natl. Acad. Sci. U. S. A.
94,
14306-14313[Abstract/Free Full Text]
|
| 95.
|
Weissenhorn, W.,
Dessen, A.,
Calder, L. J.,
Harrison, S. C.,
Skehel, J. J.,
and Wiley, D. C.
(1999)
Mol. Membr. Biol.
16,
3-9[CrossRef][Medline]
[Order article via Infotrieve]
|
| 96.
|
Jones, P. L.,
Korte, T.,
and Blumenthal, R.
(1998)
J. Biol. Chem.
273,
404-409[Abstract/Free Full Text]
|
| 97.
|
Munoz-Barroso, I.,
Durell, S.,
Sakaguchi, K.,
Appella, E.,
and Blumenthal, R.
(1998)
J. Cell Biol.
140,
315-323[Abstract/Free Full Text]
|
| 98.
|
Lu, M., Ji, H.,
and Shen, S.
(1999)
J. Virol.
73,
4433-4438[Abstract/Free Full Text]
|
| 99.
|
Dubay, J. W.,
Roberts, S. J.,
Brody, B.,
and Hunter, E.
(1992)
J. Virol.
66,
4748-4756[Abstract/Free Full Text]
|
| 100.
|
Cao, J.,
Bergeron, L.,
Helseth, E.,
Thali, M.,
Repke, H.,
and Sodroski, J.
(1993)
J. Virol.
67,
2747-2755[Abstract/Free Full Text]
|
| 101.
|
Shu, W.,
Liu, J., Ji, H.,
Radigen, L.,
Jiang, S.,
and Lu, M.
(2000)
Biochemistry
39,
1634-1642[CrossRef][Medline]
[Order article via Infotrieve]
|
| 102.
|
Chan, D. C.,
Chutkowski, C. T.,
and Kim, P. S.
(1998)
Proc. Natl. Acad. Sci. U. S. A.
95,
15613-15617[Abstract/Free Full Text]
|
| 103.
|
Chen, C. H.,
Matthews, T. J.,
McDanal, C. B.,
Bolognesi, D. P.,
and Greenberg, M. L.
(1995)
J. Virol.
69,
3771-3777[Abstract]
|
| 104.
|
Rimsky, L. T.,
Shugars, D. C.,
and Matthews, T. J.
(1998)
J. Virol.
72,
986-993[Abstract/Free Full Text]
|
| 105.
|
Chen, S. S.,
Lee, C. N.,
Lee, W. R.,
McIntosh, K.,
and Lee, T. H.
(1993)
J. Virol.
67,
3615-3619[Abstract/Free Full Text]
|
| 106.
|
Weng, Y.,
and Weiss, C. D.
(1998)
J. Virol.
72,
9676-9682[Abstract/Free Full Text]
|
Copyright © 2002 by The American Society for Biochemistry and Molecular Biology, Inc.

CiteULike Complore Connotea Del.icio.us Digg Reddit Technorati What's this?
This article has been cited by other articles:

|
 |

|
 |
 
Y. He, J. Cheng, H. Lu, J. Li, J. Hu, Z. Qi, Z. Liu, S. Jiang, and Q. Dai
Potent HIV fusion inhibitors against Enfuvirtide-resistant HIV-1 strains
PNAS,
October 21, 2008;
105(42):
16332 - 16337.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
Y. He, J. Cheng, J. Li, Z. Qi, H. Lu, M. Dong, S. Jiang, and Q. Dai
Identification of a Critical Motif for the Human Immunodeficiency Virus Type 1 (HIV-1) gp41 Core Structure: Implications for Designing Novel Anti-HIV Fusion Inhibitors
J. Virol.,
July 1, 2008;
82(13):
6349 - 6358.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
C. Sugimoto, E. E. Nakayama, T. Shioda, F. Villinger, A. A. Ansari, N. Yamamoto, Y. Suzuki, Y. Nagai, and K. Mori
Impact of glycosylation on antigenicity of simian immunodeficiency virus SIV239: induction of rapid V1/V2-specific non-neutralizing antibody and delayed neutralizing antibody following infection with an attenuated deglycosylated mutant
J. Gen. Virol.,
February 1, 2008;
89(2):
554 - 566.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
Y. He, S. Liu, W. Jing, H. Lu, D. Cai, D. J. Chin, A. K. Debnath, F. Kirchhoff, and S. Jiang
Conserved Residue Lys574 in the Cavity of HIV-1 Gp41 Coiled-coil Domain Is Critical for Six-helix Bundle Stability and Virus Entry
J. Biol. Chem.,
August 31, 2007;
282(35):
25631 - 25639.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
R. J. Center, J. Lebowitz, R. D. Leapman, and B. Moss
Promoting Trimerization of Soluble Human Immunodeficiency Virus Type 1 (HIV-1) Env through the Use of HIV-1/Simian Immunodeficiency Virus Chimeras
J. Virol.,
March 1, 2004;
78(5):
2265 - 2276.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
R. W. Sanders, M. Vesanen, N. Schuelke, A. Master, L. Schiffner, R. Kalyanaraman, M. Paluch, B. Berkhout, P. J. Maddon, W. C. Olson, et al.
Stabilization of the Soluble, Cleaved, Trimeric Form of the Envelope Glycoprotein Complex of Human Immunodeficiency Virus Type 1
J. Virol.,
July 29, 2002;
76(17):
8875 - 8889.
[Abstract]
[Full Text]
[PDF]
|
 |
|
Copyright © 2002 by the American Society for Biochemistry and Molecular Biology.
|
Advertisement
Advertisement
|